Skip to main content

Clinical Applications of Plasma Neurofilament Light in Multiple Sclerosis

Tracking # 20-1300115

Price not reported

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Broadcasted Interactive Event
Dates Contact provider

Course overview

Join our upcoming webinar to explore the role plasma neurofilament light (NfL) biomarker could have in assessing multiple sclerosis (MS) disease activity and response to therapy. The growing evidence that elevated blood NfL levels can serve as a biomarker for disease activity and treatment response in MS is expected to catalyze the need for NfL testing in clinical laboratories. In this webinar, the speakers, Drs. William Clarke and Elias Sotirchos, will focus on the clinical value and potential use of NfL in multiple sclerosis management and is meant to provide laboratory scientists with the latest insights and guidance regarding future use of NfL tests and potentially other blood biomarkers in multiple sclerosis. This webinar is essential for laboratory professionals aiming to stay at the forefront of MS diagnostics and enhance their laboratory's testing capabilities. Don't miss this opportunity to advance your understanding of this pivotal biomarker in multiple sclerosis.

Subject areas

This course counts toward the state boards and subject areas below.

American Board of Clinical Chemistry

Clinical Chemistry Diplomate

1h Category 1

Molecular Diagnostics Diplomate

1h Category 1

Toxicological Chemistry Diplomate

1h Category 1

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

1h General

Clinical Laboratory Supervisor

1h General

Clinical Laboratory Technician

1h General

Clinical Laboratory Technologist

1h General

Public Health Director

1h General

Public Health Supervisor

1h General

Public Health Technologist

1h General

Disclosure statements

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.


The following faculty reported financial relationships:

  • William Clarke, PhD, MBA, DABCC
  • Honorarium and/or Expenses: Roche Diagnostics, Werfen
  • Consulting Fees: Kinomica, Radiometer, HepQuant
  • Grant and/or Research Support: Roche Diagnostics, Radiometer, Red Abbey Labs, Truvian, Thermo Fisher Scientific
  • Committee, Board, and/or Advisory Board Memberships: Werfen, Saladax Biomedical, Truvian, Red Abbey Labs
  • Stocks and/or Bonds: Truvian, Red Abbey Labs, Saladax Biomedical


  • Elias Sotirchos, MD
  • Grant and/or Research Support: Alexion, Roche/Genentech, UCB, Ad Scientiam, Astoria Biologica, National Multiple Sclerosis Society (NMSS), National Institutes of Health (NIH), Patient Centered Outcomes Research Institute (PCORI)
  • Committee, Board, and/or Advisory Board Memberships: Alexion, Amgen, TG Therapeutics, Roche/Genentech